IL142479A0 - Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 - Google Patents

Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907

Info

Publication number
IL142479A0
IL142479A0 IL14247998A IL14247998A IL142479A0 IL 142479 A0 IL142479 A0 IL 142479A0 IL 14247998 A IL14247998 A IL 14247998A IL 14247998 A IL14247998 A IL 14247998A IL 142479 A0 IL142479 A0 IL 142479A0
Authority
IL
Israel
Prior art keywords
piperidinemethanol
dimethoxyphenyl
prodrugs
fluorophenyl
alpha
Prior art date
Application number
IL14247998A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL142479A0 publication Critical patent/IL142479A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14247998A 1998-10-14 1998-10-14 Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 IL142479A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/021608 WO2000021930A1 (fr) 1998-10-14 1998-10-14 Esters de (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol et leur utilisation comme promedicament de l'antagoniste du recepteur 5ht2a mdl 110,907

Publications (1)

Publication Number Publication Date
IL142479A0 true IL142479A0 (en) 2002-03-10

Family

ID=22268079

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14247998A IL142479A0 (en) 1998-10-14 1998-10-14 Esters of (+)-alpha-(2,3-dimethoxyphenyl) -1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907
IL142479A IL142479A (en) 1998-10-14 2001-04-05 Esters of (+) - alpha - (3,2-dimethoxyfenil) - 1 - [2 - (4 - fluorophenyl) ethyl] - 4 - piperidinemethanol, processes for their preparation, pharmaceutical compounds containing them and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142479A IL142479A (en) 1998-10-14 2001-04-05 Esters of (+) - alpha - (3,2-dimethoxyfenil) - 1 - [2 - (4 - fluorophenyl) ethyl] - 4 - piperidinemethanol, processes for their preparation, pharmaceutical compounds containing them and their uses

Country Status (21)

Country Link
EP (1) EP1121345A1 (fr)
JP (1) JP2002527422A (fr)
KR (1) KR100515429B1 (fr)
CN (1) CN1160333C (fr)
AU (1) AU1083099A (fr)
BR (1) BR9816049A (fr)
CA (1) CA2347469C (fr)
CZ (1) CZ20011331A3 (fr)
EA (1) EA003667B1 (fr)
EE (1) EE200100219A (fr)
HK (1) HK1039332A1 (fr)
HR (1) HRP20010278A2 (fr)
HU (1) HUP0200517A3 (fr)
IL (2) IL142479A0 (fr)
NO (1) NO320417B1 (fr)
NZ (1) NZ510631A (fr)
PL (1) PL193306B1 (fr)
SK (1) SK5082001A3 (fr)
TR (1) TR200101047T2 (fr)
UA (1) UA57859C2 (fr)
WO (1) WO2000021930A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
CN102241667B (zh) * 2010-05-14 2013-10-23 中国人民解放军军事医学科学院毒物药物研究所 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途
CN106892897A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种羟哌吡酮游离碱新晶型及其制备方法
CN106928187A (zh) * 2015-12-31 2017-07-07 上海奥博生物医药技术有限公司 一种盐酸羟哌吡酮新晶型及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol

Also Published As

Publication number Publication date
NZ510631A (en) 2003-07-25
UA57859C2 (uk) 2003-07-15
HUP0200517A3 (en) 2002-12-28
CN1160333C (zh) 2004-08-04
EA003667B1 (ru) 2003-08-28
EA200100361A1 (ru) 2001-10-22
NO20011805L (no) 2001-06-08
CA2347469A1 (fr) 2000-04-20
SK5082001A3 (en) 2001-11-06
PL347318A1 (en) 2002-03-25
CN1314887A (zh) 2001-09-26
AU1083099A (en) 2000-05-01
EE200100219A (et) 2002-08-15
PL193306B1 (pl) 2007-01-31
EP1121345A1 (fr) 2001-08-08
NO20011805D0 (no) 2001-04-09
HRP20010278A2 (en) 2002-06-30
HK1039332A1 (en) 2002-04-19
HUP0200517A2 (en) 2002-06-29
JP2002527422A (ja) 2002-08-27
KR100515429B1 (ko) 2005-09-20
KR20010106517A (ko) 2001-11-29
IL142479A (en) 2006-06-11
NO320417B1 (no) 2005-12-05
CZ20011331A3 (cs) 2001-08-15
CA2347469C (fr) 2006-02-28
WO2000021930A1 (fr) 2000-04-20
TR200101047T2 (tr) 2001-08-21
BR9816049A (pt) 2001-07-03

Similar Documents

Publication Publication Date Title
EG24533A (en) Piperdine derivatives useful as CCR 5 antagonists
HUP0101275A3 (en) Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
HRP980163B1 (en) Pharmaceutical composition for the oral administration of an n-piperidinopyrazole -3-carboxamide derivative, its salts and their solvates
IL122940A0 (en) Paroxetine controlled release compositions
AU5274499A (en) Therapeutic chemokine receptor antagonists
HUP0101688A3 (en) Heterocyclically substituted amides and their use for producing pharmaceutical compositions
AU5326100A (en) Pharmaceutical compositions and methods for use
AU5565099A (en) Pharmaceutical compositions and methods for use
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
PL352432A1 (en) Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them
HUP0004648A3 (en) 3-substituted tetrahydropyridopyrimidinone derivatives and their use for producing pharmaceutical compositions
HUP0002929A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
IL126022A (en) Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders
IL152908A0 (en) USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
IL127518A (en) Substituted heterocyclic benzocycloalkenes, their preparation and pharmaceutical compositions having an analgesic effect
PL333079A1 (en) Piparazinic derivatives as antagonists of neurokinin
HUP0004900A3 (en) Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
HUP0200517A3 (en) Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907
AU1573100A (en) Composition of paroxetine methanesulfonate
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
HUP0104588A3 (en) Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators pharmaceutical compositions comprising thereof, method for their preparation and their use
HUP0003548A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed